Fate therapeutics inc (FATE)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12
Collaboration revenue

10,563

10,680

9,539

8,136

6,346

4,740

4,106

4,106

4,105

4,106

4,106

4,106

4,107

4,402

4,401

3,704

0

-

0

0

-

-

-

-

-

626

834

0

0

0

Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

345

665

0

0

0

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

971

1,499

0

0

0

Operating expenses:
Research and development

99,320

87,770

76,656

67,091

62,276

56,024

51,816

46,757

37,868

34,358

30,701

28,927

27,782

26,452

25,655

23,854

21,929

19,861

18,293

17,370

16,481

16,435

15,601

14,899

13,998

12,007

12,291

0

0

0

General and administrative

26,016

23,637

21,273

19,008

17,554

15,808

14,885

13,592

12,445

11,873

10,940

10,763

10,343

9,913

10,017

9,757

10,198

10,352

9,875

9,428

8,810

8,469

8,262

8,337

7,757

6,639

5,631

0

0

0

Total operating expenses

125,336

111,407

97,929

86,099

79,830

71,832

66,701

60,349

50,313

46,231

41,641

39,690

38,125

36,365

35,672

33,611

32,127

30,213

28,168

26,798

25,291

24,904

23,863

23,236

21,755

18,646

17,922

0

0

0

Loss from operations

-114,773

-100,727

-88,390

-77,963

-73,484

-67,092

-62,595

-56,243

-46,208

-42,125

-37,535

-35,584

-34,018

-31,963

-31,221

-29,160

-28,374

-27,782

-26,813

-26,469

-25,291

-24,904

-23,863

-23,027

-21,256

-17,675

-16,423

0

0

0

Other income (expense):
Interest income

4,211

4,330

4,160

3,589

2,950

2,190

1,205

1,018

779

559

443

328

222

138

98

65

36

10

8

0

0

-

-

0

-

6

0

0

0

-

Interest expense

-

1,752

1,644

1,673

1,689

1,696

1,678

1,627

1,414

1,268

1,185

1,192

1,415

1,637

1,845

2,022

2,150

2,220

1,974

1,599

1,064

549

636

679

739

796

0

0

0

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

Change in fair value of exchangeable shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,421

0

0

0

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

0

0

0

-

Total other income, net

2,864

2,578

2,516

1,916

1,261

494

-473

-727

-753

-827

-860

-864

-1,193

-1,499

-1,747

-1,957

-2,114

-2,210

-1,966

-2,027

-1,493

-979

-1,526

-1,832

-3,070

-3,219

-2,845

0

0

0

Net loss

-111,909

-98,149

-85,874

-76,047

-72,223

-66,598

-63,068

-56,970

-46,961

-42,952

-38,395

-36,448

-35,211

-33,462

-32,968

-31,117

-30,488

-29,992

-28,779

-28,496

-26,784

-25,883

-25,389

-24,859

-24,326

-20,894

-19,268

0

0

0

Other comprehensive income (loss):
Unrealized gain on available-for-sale securities, net

142

24

65

108

13

1

-1

24

21

-2

-16

-50

-48

-1

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-111,767

-98,125

-85,809

-75,939

-72,210

-66,597

-63,069

-56,946

-46,940

-42,954

-38,411

-36,498

-35,259

-33,463

-32,965

-31,106

-30,474

-29,992

0

0

0

-

-

-

-

-

-

-

-

-

Net loss per common share, basic and diluted

-0.44

-0.38

-0.40

-0.36

-0.30

-0.24

-0.31

-0.37

-0.27

-0.29

-0.26

-0.23

-0.24

-0.20

-0.27

-0.29

-0.29

-0.23

-0.24

-0.33

-0.38

-0.31

-0.32

-0.30

-0.34

8.65

-4.81

-4.46

-2.92

-3.51

Weighted-average common shares used to compute basic and diluted net loss per share

75,886

75,699

66,929

65,213

64,920

64,703

54,185

53,130

52,763

43,705

41,428

41,406

41,388

37,280

32,090

28,868

28,777

28,811

28,650

23,920

20,554

20,503

20,489

20,467

20,346

19,869

1,262

1,239

1,213

1,171